Surender Sandella, MD
Interventional Cardiology · New Albany, INNPI 1689736324
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $16,712 of the $21,312 with a category attached, or 78.4%. It is spread thinly across 51 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $6,065 and has fallen 70.3% since, to $1,802 in 2025.
Across 504 payments — averaging $42.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Penumbra, Inc.$3K
- Boston Scientific$2K
- Johnson & Johnson$2K
- Inari Medical, Inc.$1K
- Abiomed$809
- plus $8K from 45 others
What the payments were for
- Travel & lodging$4,58121%
- Food & beverage$16,71278%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$2,889
- AVEIR$2,354
- FLOWTRIEVER CATHETER, S$1,144
- CLOTTRIEVER BOLD CATHETER$731
- Impella$586
- CT THROMBECTOMY SYSTEM KIT$517
- XARELTO$452
- FARXIGA$347
- GENERAL VASCULAR INTERVENTION$267
- NEXLIZET$247
- NEXLETOL$247
- AMPLATZER AMULET$194
- Vascular Lithotripsy$172
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$171
- Allure CRT Pacemaker$154
- LUX-Dx Insertable Cardiac Monitor$149
- KENGREAL$149
- Barostim Neo System$145
- WATCHMAN FLX$144
- Pulsar$144
How this compares
$21,312 in reported general payments places this provider in the 80th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 500 | $570,267 |
| EntrestoSacubitril/Valsartan | 131 | $155,759 |
| XareltoRivaroxaban | 64 | $91,483 |
| FarxigaDapagliflozin Propanediol | 36 | $37,891 |
| JardianceEmpagliflozin | 30 | $35,751 |
| BrilintaTicagrelor | 16 | $16,058 |
| Metoprolol Succinate | 1,335 | $14,911 |
| Repatha SyringeEvolocumab | 17 | $14,180 |
| Ranolazine ErRanolazine | 130 | $9,882 |
| Bisoprolol Fumarate | 343 | $6,310 |
| ClopidogrelClopidogrel Bisulfate | 483 | $5,077 |
| Atorvastatin Calcium | 798 | $5,032 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 589 | $4,460 |
| Candesartan Cilexetil | 30 | $4,072 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 174 | $3,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $382 | $570,267500 claims |
| NovartisEntresto | $489 | $155,759131 claims |
| Johnson & JohnsonXarelto | $1,586 | $91,48364 claims |
| AstraZenecaFarxiga, Brilinta | $765 | $53,94852 claims |
| Boehringer IngelheimJardiance | $197 | $35,75130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in New Albany
- Vikas SinghNew Albany$16K
- Srinivasarao ManchikalapudiNew Albany$12K
- Samer AbbasEast Chicago$395K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Muzammil MusaniFort Wayne$184K
- Dean FerreraEast Chicago$180K
- Shashidhar DivakaruniMunster$97K
- Jarrod FrizzellEvansville$86K
- Navneet LatherNoblesville$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.